Zealand Pharma Says EC Grants Marketing Authorization For Zeydovio, Long-Acting, Next-Gen GLP-2 Analog, For Treatment Of Adults With Short Bowel Syndrome

Zealand Pharma announces EU approval of ZeydovioTM (glepaglutide) for the treatment of short bowel syndrome

• The approval marks the first major advancement in short bowel syndrome treatment in Europe in more than a decade
• ZeydovioTM  is the first and only ready-to-use GLP-2 therapy to receive regulatory approval
• Clinically evidenced efficacy paired with simple delivery, positions ZeydovioTM as a transformative therapy for people living with short bowel syndrome
• Active enrolment into the Phase 3 EASE-5 trial to support a U.S. NDA to advance glepaglutide toward patients globally

Copenhagen, Denmark, November 13, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, today announces that the European Commission (EC) has granted marketing authorization for ZeydovioTM (glepaglutide), a long-acting, next-generation GLP-2 analog, for the treatment of adults with short bowel syndrome (SBS).